Non-alcoholic fatty liver disease (NAFLD), currently the leading cause of global chronic liver
disease, has emerged as a major public health problem, more efficient therapeutics of which …

Soft connective tissues at steady state are dynamic; resident cells continually read
environmental cues and respond to them to promote homeostasis, including maintenance of …

Nonalcoholic fatty liver disease (NAFLD) and its progressive form nonalcoholic
steatohepatitis (NASH) comprise a spectrum of chronic liver diseases in the global …

Nonalcoholic fatty liver disease (NAFLD) encompasses a range of liver pathology ranging
from simple steatosis to varying degrees of inflammation, hepatocyte injury and fibrosis …

Non‐alcoholic fatty liver disease is becoming a major health burden, as prevalence
increases and there are no approved treatment options. Thiazolidinediones target the …

Non-alcoholic fatty liver disease affects 20–40% of the population. Its active form, non-
alcoholic steatohepatitis (NASH), is characterised by hepatocyte injury, liver inflammation …

Non-alcoholic fatty liver disease (NAFLD) is a liver pathology with increasing prevalence
due to the obesity epidemic. Hence, NAFLD represents a rising threat to public health …

Background & Aims Perpetuate liver inflammation is crucial in the pathogenesis of non-
alcoholic steatohepatitis (NASH). Expression of CXCL10, a pro-inflammatory cytokine …

Abstract Non-Alcoholic Fatty Liver Disease (NAFLD) comprises a wide spectrum of liver
injuries from simple steatosis to steatohepatitis and cirrhosis. Non-Alcoholic Steatohepatitis …

Background Non-alcoholic steatohepatitis (NASH), a multifactorial disease, can progress to
hepatic fibrosis and cirrhosis. The Peroxysomal Proliferator-Activated Receptors, PPARα …